COMMUNIQUÉS West-GlobeNewswire

-
Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
01/02/2024 -
Communique de presse - 2023 : Croissance des ventes et du bénéfice net par action à TCC, succès des lancements de produits et avancée du portefeuille R&D en Immunologie
01/02/2024 -
Sandoz announces changes in the Board of Directors
01/02/2024 -
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
01/02/2024 -
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
01/02/2024 -
[Annonce événementielle au sens de l’art. 53 RC] Roche dépasse les projections et affiche une croissance des ventes de 1 % (TCC) en 2023, malgré un net recul des ventes lié au COVID-19
01/02/2024 -
Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
31/01/2024 -
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
31/01/2024 -
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
31/01/2024 -
Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to March 3, 2024
31/01/2024 -
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
31/01/2024 -
DLH Reports Fiscal 2024 First Quarter Results
31/01/2024 -
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
31/01/2024 -
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
31/01/2024 -
Nanobiotix participera à la 6ème conférence annuelle de Biotechnologie de Guggenheim
31/01/2024 -
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/01/2024 -
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
31/01/2024 -
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
31/01/2024 -
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
31/01/2024
Pages